Stryker initiated with a Neutral at UBS

UBS analyst Danielle Antalffy initiated coverage of Stryker with a Neutral rating and $287 price target as part of a sector note on U.S. Medical Supplies and Devices. Stryker is well-positioned to sustain the above-market high-single-digits sales growth rate, but UBS sees limited upside from here without meaningful upwards estimate revisions, which are unlikely, the analyst tells investors in a research note.